A real-world study showed that patients who had the classical subtype based on an RNA signature had better survival on ...

One patient with brain cancer and another with liver cancer survived more than five years without recurrence after receiving personalized cancer vaccines.

The firm is restructuring to extend its cash runway and focus resources on clinical programs, including a Phase I CAR T-cell trial in kidney cancer.

The firm, which so far has focused on cancer, expects to file an IND application for a treatment for tyrosinemia type I and alkaptonuria next year.

After the deal closes, Biogen will be in charge of developing and selling Alcyone's ThecaFlex DRx implantable subcutaneous port and catheter device.

The firm is focusing its resources on pipeline assets like IPH4502, an antibody-drug conjugate under development for treating Nectin-4-expressing cancers.

Signals from a Phase Ia trial of LP-184 in solid tumors suggested that patients with DNA damage response gene mutations might respond well to the drug.

A team from Shriners Children's and Washington University in St. Louis are investigating a new method for personalizing ...

The company has already been testing the autologous cell therapy, LioCyx-M004, in patients with certain liver cancers.

The trial will initially test the drug in patients with advanced or metastatic solid tumors and then in patients with biomarker-defined cancers.

In two Phase I expansion cohorts, the firm is studying KTX-1001 with BMS's mezigdomide or Onyx's carfilzomib in patients with t(4;14) translocations.

Investigators have used base editing to create a treatment for multisystemic smooth muscle dysfunction syndrome, which has ...